Tissue Levels of WR-1065, the Active Metabolite of Amifostine (Ethyol®), Are Equivalent following Intravenous or Subcutaneous Administration in Cynomolgus Monkeys

Christine M. Bachy,Christine Fazenbaker,Gizachew Kifle,Michael P. McCarthy,David R. Cassatt

Tissue Levels of WR-1065, the Active Metabolite of Amifostine (Ethyol®), Are Equivalent following Intravenous or Subcutaneous Administration in Cynomolgus Monkeys

2004

Christine M. Bachy
Christine Fazenbaker
Gizachew Kifle
Michael P. McCarthy
David R. Cassatt

Amifostine (Ethyol®) is a cytoprotective drug approved for the reduction of xerostomia in head and neck cancer when administered to patients receiving postoperative radiation therapy. Altho

Keywords:

Amifostine
Drug
Metabolite
Medicine
Radiation therapy
Intravenous route
Active metabolite
Head and neck cancer
Pharmacokinetics
Pharmacology
postoperative radiation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations